vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases
vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, a potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes.